Malignant Reproductive System Neoplasm

Observed

← altered in cohorts of

BCHE

226 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

CLDN16

226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

FNDC3B

226 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SLC7A14

226 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SPATA16

226 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

TBL1XR1

226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

ZBBX

226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

ABCC5

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

ACTRT3

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ATP13A5

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

BCL6

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

CLDN11

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

LPP

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

LRRC31

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

LRRC34

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

MYNN

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

P3H2

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

PEX5L

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

PLD1

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

PRKCI

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

SEC62

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SKIL

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

TP63

225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

WDR49

225 / 306 cases (74 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ABCF3

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

ACTL6A

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ATP13A4

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

ECT2

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

GHSR

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

IL1RAP

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

IQCG

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

LRRIQ4

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

MB21D2

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

MCF2L2

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

MECOM

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

NCEH1

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

OPA1

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

PHC3

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

PSMD2

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SAMD7

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SLC2A2

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SLITRK3

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts

—

Observed

← altered in cohorts of

TMEM207

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

TNFSF10

224 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

VPS8

224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

AP2M1

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

CCDC39

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

CHRD

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

DGKG

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

EIF2B5

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

EIF5A2

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

FGF12

223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

GOLIM4

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

GPR160

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

HRG

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

KCNMB2

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

LIPH

223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

MFN1

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

MRPL47

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

PIGZ

223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

PLAAT1

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

RPL22L1

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

RUBCN

223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

SERPINI2

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

SOX2

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ZMAT3

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ZNF639

223 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

ADIPOQ

222 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

CCDC50

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

CLDN1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

DLG1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

EEF1AKMT4-ECE2

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

EHHADH

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

EIF4G1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

GMNC

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

HTR3C

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

HTR3D

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

HTR3E

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

KLHL24

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

KLHL6

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

LRCH3

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

LSG1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

MCCC1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

MELTF

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

NAALADL2

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

PYDC2

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

SERPINI1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

TMEM212

222 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

TMEM44

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

TPRG1

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

UBXN7

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

USP13

222 / 306 cases (73 %) · ssm · TCGA-CESC

—

Observed

← altered in cohorts of

YEATS2

222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts

—

Observed

← altered in cohorts of

CCAR2

298 / 500 cases (60 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

BIN3

297 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

C8orf58

297 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

XPO7

297 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

BMP1

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PEBP4

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PIWIL2

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PPP3CC

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

RHOBTB2

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SORBS3

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TNFRSF10C

296 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

DMTN

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

DOK2

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

EGR3

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FAM160B2

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PDLIM2

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

POLR3D

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

REEP4

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TNFRSF10A

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TNFRSF10D

295 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CHMP7

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FGF17

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

LGI3

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

LOXL2

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NKX3-1

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NPM2

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NUDT18

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PHYHIP

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

R3HCC1

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SFTPC

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SLC25A37

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SLC39A14

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TNFRSF10B

294 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ADAM28

293 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ENTPD4

293 / 500 cases (59 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NKX2-6

292 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ADAM7

291 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ADAMDEC1

291 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

STC1

291 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

GFRA2

290 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

LZTS1

289 / 500 cases (58 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ATP6V1B2

286 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CDCA2

286 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SLC18A1

286 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

INTS10

284 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

LPL

284 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CSGALNACT1

283 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

DOCK5

283 / 500 cases (57 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

DPYSL2

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

EBF2

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

KCTD9

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NEFL

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NEFM

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PNMA2

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PPP2R2A

282 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ADRA1A

281 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

BNIP3L

281 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

GNRH1

281 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SH2D4A

279 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TRIM35

278 / 500 cases (56 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CHRNA2

277 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PSD3

277 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PTK2B

277 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

STMN4

277 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

EPHX2

276 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NAT2

275 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CCDC25

273 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ESCO2

273 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NAT1

273 / 500 cases (55 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ASAH1

272 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PCM1

272 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

CLU

271 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FGL1

271 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PBK

271 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

MTUS1

270 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SCARA3

270 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SCARA5

269 / 500 cases (54 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

NUGGC

267 / 500 cases (53 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PDGFRL

267 / 500 cases (53 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SLC7A2

267 / 500 cases (53 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ELP3

265 / 500 cases (53 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

MTMR7

262 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

PNOC

262 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

SGCZ

262 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

MSR1

261 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

TUSC3

261 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

RYR2

291 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 12 cohorts

—

Observed

← altered in cohorts of

CNOT7

260 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ZNF395

260 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

DLC1

259 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

VPS37A

259 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ZDHHC2

259 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

ASH1L

289 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 6 cohorts

—

Observed

← altered in cohorts of

C8orf48

258 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

EXTL3

258 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FBXO16

258 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FZD3

258 / 500 cases (52 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

FGF20

257 / 500 cases (51 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

LONRF1

257 / 500 cases (51 %) · ssm · TCGA-PRAD

—

Observed

← altered in cohorts of

USH2A

286 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 13 cohorts

—

Observed

← altered in cohorts of

FLG

283 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 10 cohorts

—

Observed

← altered in cohorts of

CACNA1E

281 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 7 cohorts

—

Observed

← altered in cohorts of

CEP350

277 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 3 cohorts

—

Observed

← altered in cohorts of

HRNR

277 / 559 cases (50 %) · ssm · TCGA-UCEC

—

Observed

← altered in cohorts of

ASPM

275 / 559 cases (49 %) · ssm · TCGA-UCEC · largest of 6 cohorts

—

Observed

Malignant Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 320show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 415 trials (88 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	415	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 388 trials (91 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	388	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 286 trials (49 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	286	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 255 trials (62 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	255	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 220 trials (80 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	220	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 201 trials (70 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	201	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 194 trials (45 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	194	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 167 trials (78 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	167	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 131 trials (30 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	131	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 128 trials (34 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	128	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 116 trials (51 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 115 trials (25 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	115	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 107 trials (39 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 107 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 101 trials (13 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	101	Observed	clinicaltrials	graph →

Malignant Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 320show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

415 trials (88 active) · roll-up of the cancer and its descendants

—

415

Observed

→ investigated in trials for

Carboplatinsmall molecule

388 trials (91 active) · roll-up of the cancer and its descendants

—

388

Observed

→ investigated in trials for

Docetaxelsmall molecule

286 trials (49 active) · roll-up of the cancer and its descendants

—

286

Observed

→ investigated in trials for

Cisplatinsmall molecule

255 trials (62 active) · roll-up of the cancer and its descendants

—

255

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

220 trials (80 active) · roll-up of the cancer and its descendants

—

220

Observed

→ investigated in trials for

Enzalutamidesmall molecule

201 trials (70 active) · roll-up of the cancer and its descendants

—

201

Observed

→ investigated in trials for

Prednisonesmall molecule

194 trials (45 active) · roll-up of the cancer and its descendants

—

194

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

167 trials (78 active) · roll-up of the cancer and its descendants

—

167

Observed

→ investigated in trials for

Leuprolideother

131 trials (30 active) · roll-up of the cancer and its descendants

—

131

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

128 trials (34 active) · roll-up of the cancer and its descendants

—

128

Observed

→ investigated in trials for

Olaparibsmall molecule

116 trials (51 active) · roll-up of the cancer and its descendants

—

116

Observed

→ investigated in trials for

Gemcitabinesmall molecule

115 trials (25 active) · roll-up of the cancer and its descendants

—

115

Observed

→ investigated in trials for

Abiraterone Acetatesmall molecule

107 trials (39 active) · roll-up of the cancer and its descendants

—

107

Observed

→ investigated in trials for

Bicalutamidesmall molecule

107 trials (17 active) · roll-up of the cancer and its descendants

—

107

Observed

→ investigated in trials for

Topotecansmall molecule

101 trials (13 active) · roll-up of the cancer and its descendants

—

101

Observed

Malignant Prostate Neoplasm

Malignant Reproductive System Neoplasm studied in …STUDIED_INderived10 of 10,991show all (up to 200)
→ studied in	NCT01230866Phase 3 · active not recruiting Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Testicular Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01492972Phase 3 · recruiting Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Cervical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)	—	—	Penile Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05051722recruiting Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Cervical Neoplasm	1	Observed	clinicaltrials	graph →

Malignant Reproductive System Neoplasm studied in …STUDIED_INderived10 of 10,991show all (up to 200)

→ studied in

NCT01230866Phase 3 · active not recruiting

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

Malignant Testicular Neoplasm

→ studied in

NCT01242072Phase 1 · completed

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

Malignant Prostate Neoplasm

→ studied in

NCT01492972Phase 3 · recruiting

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

→ studied in

NCT02345265Phase 2 · active not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)

—

Fallopian Tube Carcinoma

Observed

Fallopian Tube Clear Cell Adenocarcinoma

→ studied in

NCT02446600Phase 3 · active not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

Fallopian Tube Clear Cell Adenocarcinoma

→ studied in

NCT02502266Phase 2/Phase 3 · active not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)

—

Observed

Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT03348631Phase 2 · active not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)

—

Observed

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)

—

Penile Carcinoma

Observed

Malignant Cervical Neoplasm

→ studied in

NCT05051722recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)

—

Observed